QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NYSE:ADCT

ADC Therapeutics Stock Forecast, Price & News

$28.00
+0.81 (+2.98 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$26.40
$28.00
50-Day Range
$23.32
$30.00
52-Week Range
$20.01
$38.34
Volume
231,472 shs
Average Volume
279,647 shs
Market Capitalization
$1.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.14
30 days | 90 days | 365 days | Advanced Chart
Receive ADCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


ADC Therapeutics logo

About ADC Therapeutics

ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
208
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.34 million
Book Value
$4.87 per share

Profitability

Net Income
$-246.29 million
Pretax Margin
-5,316.04%

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$1.93 billion
Next Earnings Date
11/11/2021 (Estimated)
Fiscal Year End
December 31
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.96 out of 5 stars

Medical Sector

612th out of 1,372 stocks

Pharmaceutical Preparations Industry

291st out of 669 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -












ADC Therapeutics (NYSE:ADCT) Frequently Asked Questions

Is ADC Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADC Therapeutics stock.
View analyst ratings for ADC Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than ADC Therapeutics?

Wall Street analysts have given ADC Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADC Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is ADC Therapeutics' next earnings date?

ADC Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 11th 2021.
View our earnings forecast for ADC Therapeutics
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) posted its quarterly earnings data on Monday, August, 2nd. The company reported ($0.96) EPS for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.10. The company had revenue of $3.76 million for the quarter, compared to analysts' expectations of $5.70 million.
View ADC Therapeutics' earnings history
.

What price target have analysts set for ADCT?

5 brokerages have issued 1-year target prices for ADC Therapeutics' stock. Their forecasts range from $33.00 to $55.00. On average, they anticipate ADC Therapeutics' stock price to reach $44.60 in the next twelve months. This suggests a possible upside of 59.3% from the stock's current price.
View analysts' price targets for ADC Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are ADC Therapeutics' key executives?

ADC Therapeutics' management team includes the following people:
  • Dr. Christopher J. Martin, Co-Founder, CEO & Director (Age 62)
  • Mr. Michael Forer L.L.B., Vice Chairman, Exec. VP & Gen. Counsel (Age 55)
  • Ms. Jennifer Creel, Chief Financial Officer (Age 50)
  • Mr. Robert A. Schmidt, VP, Corp. Controller & Chief Accounting Officer (Age 44)
  • Amanda Hamilton, Investor Relations Officer
  • Ms. Susan Romanus, Chief Compliance Officer (Age 55)
  • Dr. Peter Greaney Ph.D., Head of Corp. Devel. (Age 41)
  • Ms. Kimberly Pope, Sr. VP & Chief HR Officer (Age 54)
  • Dr. Patrick van Berkel, Sr. VP of R&D (Age 52)
  • Dr. Jay M. Feingold M.D., Ph.D., Chief Medical Officer, Head of Oncology Clinical Devel. & Sr. VP (Age 64)

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include Honeywell International (HON), CVS Health (CVS), Raytheon Technologies (RTX), The Home Depot (HD), The Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company served as the underwriters for the IPO.

What is ADC Therapeutics' stock symbol?

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

How do I buy shares of ADC Therapeutics?

Shares of ADCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADC Therapeutics' stock price today?

One share of ADCT stock can currently be purchased for approximately $28.00.

How much money does ADC Therapeutics make?

ADC Therapeutics has a market capitalization of $1.93 billion and generates $2.34 million in revenue each year. The company earns $-246.29 million in net income (profit) each year or ($3.77) on an earnings per share basis.

How many employees does ADC Therapeutics have?

ADC Therapeutics employs 208 workers across the globe.

What is ADC Therapeutics' official website?

The official website for ADC Therapeutics is www.adctherapeutics.com.

How can I contact ADC Therapeutics?

The company can be reached via phone at 41-21-653-0200 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.